NDLI: Pharmacological treatments of cerebellar ataxia

Please wait, while we are loading the content...

Down-regulation of the AMPA glutamate receptor subunits GluR1 and GluR2/3 in the rat cerebellum following pre- and perinatal Δ$^{9}$-tetrahydrocannabinol exposure

Use of sequence information in associative learning in control subjects and cerebellar patients

Expression and possible role of neuronal calcium sensor-1 in the cerebellum

The δ2 glutamate receptor: a key molecule controlling synaptic plasticity and structure in Purkinje cells

The role of the extracellular signal-regulated kinase pathway in cerebellar abnormalities in schizophrenia

Impact of thyroid hormone deficiency on the developing CNS: cerebellar glial and neuronal protein expression in rat neonates exposed to antithyroid drug propylthiouracil

Pharmacological treatments of cerebellar ataxia

Synaptic shunting by a baseline of synaptic conductances modulates responses to inhibitory input volleys in cerebellar Purkinje cells

Epilepsia partialis continua possibly caused by cerebellar lesion

The Cerebellum : Volume 3, Issue 1, March 2004

The Cerebellum : Volume 2

The Cerebellum : Volume 1

Pharmacological treatments of cerebellar ataxia

Content Provider	Springer Nature Link
Author	Ogawa, Masafumi
Copyright Year	2004
Abstract	The confirmed pharmacological treatment of cerebellar ataxia is still lacking. In a recent preliminary trial, we showed that D-cycloserine, a partial NMDA allosteric agonist, may relieve the symptoms. In this paper, major clinical trials to relieve ataxic symptoms are reviewed. Previous studies showed some efficacy of physostigmine in ataxic patients. However, physostigmine did not improve the ataxia in a recent double-blind crossover study. The replacement therapy of the deficient cholinergic system with choline or choline derivatives was tried in patients with Friedreich’s ataxia and other ataxic patients, but the result was not definitive. A levorotatory form of hydroxytryptophan (a serotonin precursor), a serotoninergic 5-HT1A agonist, a serotoninergic 5-HT3 antagonist, and a serotonin reuptake inhibitor were also used for the therapy for ataxia. In a double-blind randomized study, buspirone, a 5-HT1A agonist was active in cerebellar ataxia, but the effect is partial and not major. The effects of the studies with the other serotoninergic drugs were not consistent. The effect of sulfamethoxazole-trimethoprim therapy in spinocerebellar ataxia type3/Machado-Joseph disease (MJD) was reported, although the therapy improved spasticity or rigidity, rather than ataxia. In contrast to previous studies, sulfamethoxazole-trimethoprim therapy in MJD had no effect in a {dy2001} double-blind crossover study. The thyrotropin-releasing hormone, D-cycloserine, and acetazolamide for SCA6 may have some efficacy. However, a well-designed double-blind crossover trial is needed to confirm the effect.
Starting Page	107
Ending Page	111
Page Count	5
File Format	PDF
ISSN	14734222
Journal	The Cerebellum
Volume Number	3
Issue Number	2
e-ISSN	14734230
Language	English
Publisher	Springer-Verlag
Publisher Date	2004-01-01
Publisher Place	New York
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	pharmacological treatment cerebellar ataxia study design D-cycloserine Neurosciences Neurobiology Neurology
Content Type	Text
Resource Type	Article
Subject	Neurology Neurology (clinical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Cerebellar Stimulation in Ataxia

Spinocerebellar ataxia type 15

Sudden Stopping in Patients with Cerebellar Ataxia

A Comprehensive Review of Spinocerebellar Ataxia Type 2 in Cuba

Cerebellar TMS in Treatment of a Patient with Cerebellar Ataxia: Evidence from Clinical, Biomechanics and Neurophysiological Assessments

Treatment of cerebellar ataxia with 5-HT1A agonist

Spinocerebellar ataxia type 20

Cerebellar ataxia associated with anti-glutamic acid decarboxylase autoantibodies

Prevalence Rate and Functional Status of Cerebellar Ataxia in Korea

Pharmacological treatments of cerebellar ataxia

Similar Documents

Cerebellar Stimulation in Ataxia

Spinocerebellar ataxia type 15

Sudden Stopping in Patients with Cerebellar Ataxia

A Comprehensive Review of Spinocerebellar Ataxia Type 2 in Cuba

Cerebellar TMS in Treatment of a Patient with Cerebellar Ataxia: Evidence from Clinical, Biomechanics and Neurophysiological Assessments

Treatment of cerebellar ataxia with 5-HT1A agonist

Spinocerebellar ataxia type 20

Cerebellar ataxia associated with anti-glutamic acid decarboxylase autoantibodies

Prevalence Rate and Functional Status of Cerebellar Ataxia in Korea

Pharmacological treatments of cerebellar ataxia